ATE378330T1 - Trizyklische thrombin rezeptor antagonisten - Google Patents

Trizyklische thrombin rezeptor antagonisten

Info

Publication number
ATE378330T1
ATE378330T1 AT03718393T AT03718393T ATE378330T1 AT E378330 T1 ATE378330 T1 AT E378330T1 AT 03718393 T AT03718393 T AT 03718393T AT 03718393 T AT03718393 T AT 03718393T AT E378330 T1 ATE378330 T1 AT E378330T1
Authority
AT
Austria
Prior art keywords
receptor antagonists
thrombin receptor
tricyclic thrombin
tricyclic
antagonists
Prior art date
Application number
AT03718393T
Other languages
English (en)
Inventor
Samuel Chackalamannil
Martin Clasby
William Greenlee
Yuguang Wang
Yan Xia
Enrico Veltri
Mariappan Chelliah
Wenxue Wu
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29250954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE378330(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE378330T1 publication Critical patent/ATE378330T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
AT03718393T 2002-04-16 2003-04-14 Trizyklische thrombin rezeptor antagonisten ATE378330T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37307202P 2002-04-16 2002-04-16

Publications (1)

Publication Number Publication Date
ATE378330T1 true ATE378330T1 (de) 2007-11-15

Family

ID=29250954

Family Applications (3)

Application Number Title Priority Date Filing Date
AT07016461T ATE455774T1 (de) 2002-04-16 2003-04-14 Trizyklische thrombinrezeptorantagonisten
AT03718393T ATE378330T1 (de) 2002-04-16 2003-04-14 Trizyklische thrombin rezeptor antagonisten
AT09150995T ATE494284T1 (de) 2002-04-16 2003-04-14 Tricyclischer thrombinrezeptorantagonist

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT07016461T ATE455774T1 (de) 2002-04-16 2003-04-14 Trizyklische thrombinrezeptorantagonisten

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT09150995T ATE494284T1 (de) 2002-04-16 2003-04-14 Tricyclischer thrombinrezeptorantagonist

Country Status (34)

Country Link
US (3) US7304078B2 (de)
EP (5) EP1495018B3 (de)
JP (2) JP4558331B2 (de)
KR (1) KR101026929B1 (de)
CN (1) CN1659162B (de)
AR (1) AR039570A1 (de)
AT (3) ATE455774T1 (de)
AU (1) AU2003221932B2 (de)
BR (1) BRPI0309309B8 (de)
CA (1) CA2482858C (de)
CY (3) CY1107184T1 (de)
DE (3) DE60317493T3 (de)
DK (2) DK2065384T3 (de)
EC (1) ECSP045368A (de)
ES (3) ES2357876T3 (de)
FR (1) FR15C0047I2 (de)
HK (3) HK1070887A1 (de)
IL (1) IL164585A (de)
LT (1) LTC1495018I2 (de)
LU (1) LU92759I2 (de)
MX (1) MXPA04010308A (de)
MY (1) MY144040A (de)
NL (1) NL300746I1 (de)
NO (2) NO330500B1 (de)
NZ (2) NZ575139A (de)
PE (1) PE20040412A1 (de)
PL (1) PL214718B1 (de)
PT (2) PT2065384E (de)
RU (2) RU2329264C9 (de)
SG (1) SG164279A1 (de)
SI (2) SI1495018T1 (de)
TW (1) TWI343919B (de)
WO (1) WO2003089428A1 (de)
ZA (1) ZA200408342B (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US7442712B2 (en) * 2004-05-28 2008-10-28 Schering Corporation Constrained himbacine analogs as thrombin receptor antagonists
WO2006042017A2 (en) * 2004-10-06 2006-04-20 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
US7541471B2 (en) * 2005-01-14 2009-06-02 Schering Corporation Synthesis of himbacine analogs
US20060172397A1 (en) * 2005-01-14 2006-08-03 Schering Corporation Preparation of chiral propargylic alcohol and ester intermediates of himbacine analogs
WO2006076452A2 (en) * 2005-01-14 2006-07-20 Schering Corporation An exo-selective synthesis of himbacine analogs
DE602006020414D1 (en) * 2005-01-14 2011-04-14 Schering Corp Synthese von himbacinanaloga
ATE458726T1 (de) * 2005-01-14 2010-03-15 Schering Corp Exo- und diastereoselektive synthese von himbacin-analoga
WO2006105217A2 (en) 2005-03-31 2006-10-05 Schering Corporation Spirocyclic thrombin receptor antagonists
WO2007075808A2 (en) * 2005-12-20 2007-07-05 Schering Corporation Methods for preventing and/or treating a cell proliferative disorder
CN101384259A (zh) * 2005-12-22 2009-03-11 先灵公司 作为预防来自心肺外科手术的并发症的凝血酶受体拮抗剂
PE20080183A1 (es) * 2006-04-06 2008-03-10 Schering Corp Terapias de combinacion de tra
WO2007120730A2 (en) 2006-04-13 2007-10-25 Schering Corporation Fused ring thrombin receptor antagonists
WO2008005262A1 (en) * 2006-06-29 2008-01-10 Schering Corporation Substituted bicyclic and tricyclic thrombin receptor antagonists
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
AR061727A1 (es) * 2006-06-30 2008-09-17 Schering Corp Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato
DE102006036023A1 (de) 2006-08-02 2008-02-07 Sanofi-Aventis Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
AR063095A1 (es) * 2006-10-04 2008-12-30 Schering Corp Antagonistas del receptor de trombina basados en la unidad triciclica modificada de himbacina
CN101541782A (zh) 2006-10-04 2009-09-23 先灵公司 作为凝血酶受体拮抗剂的二环和三环衍生物
EP2120879A2 (de) * 2006-12-22 2009-11-25 Schering Corporation Desintegrationspromoter in nassgranulat-formulierungen mit fester dosierung
US20080234236A1 (en) * 2007-03-23 2008-09-25 Veltri Enrico P Reduction of adverse events after percutaneous intervention by use of a thrombin receptor antagonist
AU2009211888B2 (en) 2008-02-05 2013-06-20 Sanofi Triazolium salts as PAR1 inhibitors, production thereof, and use as medicaments
DK2240487T3 (da) 2008-02-05 2012-04-02 Sanofi Sa Triazolopyridaziner som para-inhibitorer, fremstilling og anvendelse heraf som lægemiddel
WO2009124103A2 (en) * 2008-04-02 2009-10-08 Schering Corporation Combination therapies comprising par1 antagonists with par4 antagonists
CA2724430A1 (en) 2008-05-19 2009-11-26 Schering Corporation Heterocyclic compounds as factor ixa inhibitors
JP5789256B2 (ja) 2009-06-04 2015-10-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． トロンビン受容体アンタゴニストの活性代謝物
CA2764172A1 (en) 2009-06-08 2010-12-16 Schering Corporation A thrombin receptor antagonist and clopidogrel fixed dose tablet
EP2462123B1 (de) 2009-08-04 2013-10-02 Merck Sharp & Dohme Corp. 4,5,6-trisubstituierte pyrimidin- derivate als factor ixa inhibitoren
PL2558462T3 (pl) 2010-04-16 2015-03-31 Sanofi Sa Pirydylo-winylo-pirazolo-chinoliny jako inhibitory PAR1
PL2558465T3 (pl) 2010-04-16 2015-05-29 Sanofi Sa Trycykliczne pirydylo-winylo-pirole jako inhibitory receptora aktywowanego proteazą 1 (PAR1)
KR101303348B1 (ko) 2010-06-25 2013-09-03 한국화학연구원 트롬빈 수용체 길항제인 ［6＋5］접합 바이사이클, 그의 제조방법 및 그를 포함하는 약제학적 조성물
WO2013134012A1 (en) 2012-03-06 2013-09-12 Merck Sharp & Dohme Corp. Preparation and use of bicyclic himbacine derivatives as par-receptor antagonists
WO2015013083A1 (en) * 2013-07-22 2015-01-29 Merck Sharp & Dohme Corp. Co-crystal of the par-1 receptor antagonist vorapaxar and aspirin
US9701669B2 (en) 2013-08-22 2017-07-11 Merck Sharp & Dohme Corp. Preparation and use of 7a-amide substituted- 6,6-difluoro bicyclic himbacine derivatives as PAR-1 receptor antagonists
WO2015026686A1 (en) * 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. 3'-pyridyl substituted- 6,6-difluoro bicyclic himbacine derivatives
WO2015026685A1 (en) * 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. 7a-heterocycle substituted- 6, 6-difluoro bicyclic himbacine derivatives
FR3014693B1 (fr) 2013-12-16 2016-01-08 Pf Medicament Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
EP3131897B8 (de) 2014-04-16 2022-08-03 Merck Sharp & Dohme LLC Faktor-ixa-hemmer
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN105985303B (zh) * 2015-02-13 2020-08-14 上海彩迩文生化科技有限公司 抗凝血剂的制备方法、中间体及其制备方法
CN106478608A (zh) * 2015-09-01 2017-03-08 博瑞生物医药（苏州）股份有限公司 沃拉帕沙的硫酸盐的结晶多晶型物
CN106749201A (zh) * 2015-11-25 2017-05-31 博瑞生物医药（苏州）股份有限公司 一种沃拉帕沙及其中间体的制备方法
WO2017134200A1 (en) * 2016-02-05 2017-08-10 Sanovel Ilac Sanayi Ve Ticaret A.S. A novel pharmaceutical composition of vorapaxar and metoprolol
TR201601548A2 (tr) * 2016-02-05 2018-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu
TW201738221A (zh) * 2016-04-22 2017-11-01 Jiangsu Tasly Diyi Pharmaceutical Co Ltd 新的喜巴辛類似物、其藥物組合物及其在醫藥中的應用
CN106236779A (zh) * 2016-08-22 2016-12-21 孔五 一种脐带血富血小板血浆prp的制备方法
FR3090317B1 (fr) 2018-12-19 2021-05-07 Cvasthera Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale
CN110407819B (zh) * 2019-08-02 2020-06-26 牡丹江医学院 一种作为预防外科手术并发症的凝血酶受体拮抗剂
US20210113536A1 (en) * 2019-10-21 2021-04-22 United States Government as Represented by the Department of Veteran Affairs Methods and compositions for detecting and treating venous thromboembolism
FR3109089B1 (fr) 2020-04-08 2023-04-14 Cvasthera Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales
WO2022018156A1 (en) 2020-07-22 2022-01-27 Janssen Pharmaceutica Nv Compounds useful as factor xia inhibitors
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
US11897880B2 (en) 2021-04-30 2024-02-13 Janssen Pharmaceutica Nv 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
US11958856B2 (en) 2021-07-22 2024-04-16 Janssen Pharmaceutica Nv Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors
FR3134314A1 (fr) 2022-04-08 2023-10-13 Cvasthera Composition pharmaceutique à base de vorapaxar et son utilisation pour le traitement des maladies inflammatoires intestinales

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623810B2 (fr) 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
IL106197A (en) 1992-07-30 1999-11-30 Cor Therapeutics Inc Agagonists for the rhombin receptors and pharmaceutical preparations containing them
US5576328A (en) 1994-01-31 1996-11-19 Elf Sanofi Method for the secondary prevention of ischemic events
NZ504218A (en) * 1997-11-25 2002-04-26 Schering Corp Thrombin receptor antagonists
US6063847A (en) * 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
FR2779726B1 (fr) 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
MXPA02012447A (es) * 2000-06-15 2003-04-25 Schering Corp Antagonistas receptores de trombina.
MY139335A (en) 2001-10-18 2009-09-30 Schering Corp Substituted tricyclic himbacine derivatives that are useful as thrombin receptor antagonists

Also Published As

Publication number Publication date
SI1495018T1 (sl) 2008-04-30
MXPA04010308A (es) 2005-02-03
NO20044963L (no) 2004-11-15
ECSP045368A (es) 2005-01-03
KR101026929B1 (ko) 2011-04-04
ATE455774T1 (de) 2010-02-15
CA2482858A1 (en) 2003-10-30
BR0309309A (pt) 2005-02-15
NL300746I2 (de) 2016-01-21
DK1495018T3 (da) 2008-02-18
ES2297150T3 (es) 2008-05-01
FR15C0047I2 (fr) 2016-05-06
HK1123302A1 (en) 2009-06-12
RU2004133375A (ru) 2005-07-10
JP4558331B2 (ja) 2010-10-06
IL164585A (en) 2010-11-30
ES2357876T3 (es) 2011-05-03
PT1495018E (pt) 2008-02-19
CY1107184T1 (el) 2012-10-24
AU2003221932B2 (en) 2007-11-22
EP1495018A1 (de) 2005-01-12
NL300746I1 (de) 2016-01-21
RU2329264C2 (ru) 2008-07-20
ATE494284T1 (de) 2011-01-15
KR20040099441A (ko) 2004-11-26
NZ535880A (en) 2007-11-30
CN1659162A (zh) 2005-08-24
SI2065384T1 (sl) 2011-05-31
US7304078B2 (en) 2007-12-04
DE60317493T2 (de) 2008-09-18
EP1982984A2 (de) 2008-10-22
EP1860106B1 (de) 2010-01-20
BRPI0309309B1 (pt) 2018-09-04
EP1495018B1 (de) 2007-11-14
CY2015029I2 (el) 2016-04-13
RU2329264C9 (ru) 2009-04-20
JP2005528406A (ja) 2005-09-22
DE60335679D1 (de) 2011-02-17
NO2015016I2 (no) 2015-07-09
US20070179187A1 (en) 2007-08-02
NZ575139A (en) 2010-08-27
EP1982984A3 (de) 2008-10-29
CA2482858C (en) 2010-11-30
SG164279A1 (en) 2010-09-29
ES2297150T7 (es) 2012-03-16
EP2065384A1 (de) 2009-06-03
DE60331114D1 (de) 2010-03-11
AU2003221932A1 (en) 2003-11-03
IL164585A0 (en) 2005-12-18
CN1659162B (zh) 2011-08-31
DK2065384T3 (da) 2011-05-02
PL214718B1 (pl) 2013-09-30
PE20040412A1 (es) 2004-07-12
LU92759I2 (en) 2015-08-31
AR039570A1 (es) 2005-02-23
CY1111363T1 (el) 2015-08-05
US7713999B2 (en) 2010-05-11
JP2010132710A (ja) 2010-06-17
EP2062890A1 (de) 2009-05-27
WO2003089428A1 (en) 2003-10-30
NO2015016I1 (no) 2015-07-20
US20070270439A1 (en) 2007-11-22
ES2338171T3 (es) 2010-05-04
TW200404068A (en) 2004-03-16
PL373332A1 (en) 2005-08-22
DE60317493D1 (en) 2011-01-13
BRPI0309309B8 (pt) 2021-05-25
CY2015029I1 (el) 2016-04-13
RU2008106401A (ru) 2009-08-27
US20030216437A1 (en) 2003-11-20
EP2062890B1 (de) 2011-01-05
FR15C0047I1 (de) 2015-08-28
EP1495018B3 (de) 2011-03-16
ZA200408342B (en) 2006-05-31
DE60317493T3 (de) 2018-07-12
PT2065384E (pt) 2011-03-16
EP1860106A1 (de) 2007-11-28
EP2065384B1 (de) 2011-01-05
HK1070887A1 (en) 2005-06-30
EP1982984B1 (de) 2013-02-13
TWI343919B (en) 2011-06-21
HK1129893A1 (en) 2009-12-11
NO330500B1 (no) 2011-05-02
LTC1495018I2 (lt) 2017-04-10
MY144040A (en) 2011-07-29

Similar Documents

Publication Publication Date Title
CY2015029I2 (el) Τρικυκλικοι ανταγωνιστες υποδοχεα θρομβινης
ATE413400T1 (de) Cgrp-rezeptorantagonisten
IL174538A0 (en) Thrombin receptor antagonists
ATE368659T1 (de) Thrombinrezeptorantagonisten
NO20051871D0 (no) Opioid reseptorantagonister
DK1682142T3 (da) M3-muscarin-acetylcholin-receptor-antagonister
ATE525378T1 (de) Himbacinanaloga als thrombinrezeptorantagonisten
ATE452886T1 (de) Chemokinrezeptorantagonisten
DE602004030930D1 (de) Muscarinische acetylcholin-rezeptor-antagonisten
ATE382034T1 (de) Hydroisoindolin-tachykininrezeptorantagonisten
ZA200702790B (en) Thrombin receptor antagonists
DE60332816D1 (de) Nk1-antagonisten
ATE320254T1 (de) Crf receptor antagonisten
EP1534736A4 (de) Antagonisten des nogo-rezeptors
SE0003996D0 (sv) Receptorantagonister

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1495018

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1495018

Country of ref document: EP